Latest News

New results from the RAMPART trial found that giving durvalumab alone did not help prevent kidney cancer from coming back after surgery compared to active monitoring.
The REFINE-MS trial will evaluate if people living with relapsing-remitting MS can take treatment less often while keeping their disease activity under control.

An AI technology is effective at planning the delivery of life-saving radiotherapy for cervical cancer and prostate cancer, according to results from a large international trial led by researchers at UCL and the London School of Hygiene & Tropical Medicine (LSHTM). For cervical cancer, 94% of deaths occur in low- and middle-income countries (350,000 women died in 2022). Ra ...

Analysis from the STAMPEDE trial shows that combining a PSA blood test with information about cancer burden at diagnosis predicts survival more accurately than PSA levels alone.
BREATHER+ results published in The Lancet HIV confirm that taking HIV medicines every day without breaks remains the best way to keep the virus under control.